Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019.
China
clinical trial
endocrine disorder
metabolism and nutrition disorder
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
13
09
2020
revised:
18
01
2021
accepted:
19
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
17
12
2021
Statut:
ppublish
Résumé
With the improvements in relevant policies, laws, and regulations regarding drug clinical trials in China, the quantity and quality of drug clinical trials have gradually improved, and the development prospects of drug clinical trials for endocrine disorders and metabolism and nutrition disorders are promising. Based on information from the clinical trials from the online drug clinical trial registration platform of the National Medical Products Administration, we aimed to review and evaluate the development of clinical trials of drugs for endocrine disorders and metabolism and nutrition disorders in mainland China from 2010 to 2019, as well as the trends over time. A total of 861 trials were carried out on 254 types of drugs for endocrine disorders and metabolism and nutrition disorders, among which 531 (61.67%) involved endocrine disorders, and 330 (38.33%) addressed metabolism and nutrition disorders. The annual number of clinical trials has been increasing gradually, with a significant increase in 2017. Among them, the proportion of clinical trials with Chinese epidemiological characteristics was relatively large (Wu, Annual Report on Development Health Management and Health Industry in China, 2018). The largest number of trials were for diabetes drugs (55.63%), followed by trials of drugs for hyperlipidemia (19.4%) and those for hyperuricemia (7.9%). It was found that the geographical area of the leading units also showed obvious unevenness according to the analysis of the test unit data. Based on the statistics and evaluation of the data, comprehensive information is provided to support the cooperation of global pharmaceutical R&D companies and research units in China and the development of international multicenter clinical trials in China. This work additionally provides clinical trial units with a self-evaluation of scientific research competitiveness and hospital development strategies. At the same time, it provides a reference with basic data for sponsors and stakeholders in these trials to determine their development strategy goals.
Identifiants
pubmed: 33660404
doi: 10.1002/prp2.729
pmc: PMC7931124
doi:
Types de publication
Historical Article
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00729Informations de copyright
© 2021 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Références
Lancet Oncol. 2019 Feb;20(2):183-186
pubmed: 30723039
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
Curr Med Res Opin. 2017 Apr;33(4):693-699
pubmed: 28035868
Expert Opin Drug Saf. 2016;15(2):249-64
pubmed: 26607297
Int J Mol Sci. 2020 Mar 25;21(7):
pubmed: 32218354
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Circ Res. 2018 May 11;122(10):1439-1459
pubmed: 29748368
Diabetes Care. 2004 May;27(5):1047-53
pubmed: 15111519
Lancet Oncol. 2017 Jul;18(7):855
pubmed: 28552212
Nat Rev Clin Oncol. 2017 Sep;14(9):577-583
pubmed: 28195238
Pancreatology. 2016 Jan-Feb;16(1):8-9
pubmed: 26138513
Expert Opin Drug Metab Toxicol. 2014 Apr;10(4):599-608
pubmed: 24547938
Clin Chem Lab Med. 2016 Jan;54(1):7-15
pubmed: 26351943
Diabetes Metab. 2019 Jun;45(3):286-293
pubmed: 30196138
Drug Saf. 2019 Nov;42(11):1311-1327
pubmed: 31654243
Lancet. 2008 Nov 8;372(9650):1697-705
pubmed: 18930526
Clin Pharmacokinet. 2016 Jun;55(6):657-72
pubmed: 26597252